Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedra studies

This article was originally published in The Tan Sheet

Executive Summary

The Ephedra Education Council has assembled a panel of researchers to study the supplement ingredient's safety profile in light of FDA's recent AER review, the industry group announces July 25. EEC charges FDA's approach to ephedra safety "has serious scientific limitations," echoing past comments by Metabolife and the General Accounting Office (1"The Tan Sheet" Aug. 9, 1999, p. 3). The council has asked FDA that the panel, chaired by Stephen Kimmel, MD, University of Pennsylvania, be permitted to present its findings at the Aug. 8 public meeting on ephedra (2"The Tan Sheet" June 12, In Brief). Metabolife is among the sponsors of a safety study conducted by Carol Boozer, St. Lukes-Roosevelt Hospital Center, New York City, who is evaluating data and will attend the public meeting
Advertisement

Related Content

Ephedrine/Caffeine Combos Safer Than Ephedrine Alone - Researcher
Ephedrine/Caffeine Combos Safer Than Ephedrine Alone - Researcher
Ephedrine/Caffeine Combos Safer Than Ephedrine Alone - Researcher
Ephedra meeting
FDA Ephedrine Adverse Event Data Questioned By GAO
FDA Ephedrine Adverse Event Data Questioned By GAO

Topics

Advertisement
UsernamePublicRestriction

Register

PS091483

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel